Literature DB >> 28866416

Upregulation of miR-3607 promotes lung adenocarcinoma proliferation by suppressing APC expression.

Yong Lin1, Qiangye Gu2, Zongwen Sun3, Baowei Sheng1, Congcong Qi1, Bing Liu1, Tian Fu1, Cun Liu4, Yan Zhang5.   

Abstract

Lung cancer is the leading cause of worldwide cancer-related deaths, although many drugs and new therapeutic approaches have been used, the 5-years survival rate is still low for lung cancer patients. microRNAs have been shown to regulate lung cancer initiation and development, here we studied the role of miR-3607 in lung cancer cell proliferation. We found miR-3607 was upregulated in lung cancer tissues and cells, miR-3607 overexpression promoted lung cancer cell A549 proliferation determined by MTT assay, colony formation assay, anchorage-independent growth ability assay and bromodeoxyuridine incorporation assay, while the opposite phenotypes were shown when miR-3607 was knocked down. Predicted analysis suggested a Wnt signaling pathway regulator adenomatous polyposis coli (APC) was the target of miR-3607, miR-3607 could directly bind to the 3'UTR of APC, and promoted Cyclin D1 and c-Myc expression which can be suppressed by APC. Double knockdown of miR-3607 and APC copied the phenotypes of miR-3607 overexpression, suggesting miR-3607 promoted lung cancer cell A549 proliferation by targeting APC. In conclusion, our study suggested miR-3607 contributes to lung cancer cell proliferation by inhibiting APC.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  APC; Cell proliferation; Lung cancer; c-Myc; miR-3607

Mesh:

Substances:

Year:  2017        PMID: 28866416     DOI: 10.1016/j.biopha.2017.08.052

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  The Oncogenic Role of miR-BART19-3p in Epstein-Barr Virus-Associated Diseases.

Authors:  Qingxun Zhang; Donghua Luo; Zhengde Xie; Hongxuan He; Ziyuan Duan
Journal:  Biomed Res Int       Date:  2020-07-02       Impact factor: 3.411

2.  Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion.

Authors:  Wenwen Dou; Min Yang; Yan Su; Ruizhu Xie
Journal:  Diagn Pathol       Date:  2020-05-13       Impact factor: 2.644

3.  miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.

Authors:  Peng Gao; Huan Wang; Jiarui Yu; Jie Zhang; Zhao Yang; Meiyue Liu; Yi Niu; Xiaomei Wei; Wei Wang; Hongmin Li; Yadi Wang; Guogui Sun
Journal:  PLoS Genet       Date:  2018-12-17       Impact factor: 5.917

4.  MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein.

Authors:  Xiaoli Wei; Mengru Gao; Yaser Ahmed; Min Gao; Wenbo Liu; Yiyin Zhang; Xiaoque Xie; Qihong Zhao; Hua Wang; Kangsheng Gu
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

5.  miR‑501‑3p promotes colorectal cancer progression via activation of Wnt/β‑catenin signaling.

Authors:  Fangxiong Wu; Tongchao Xing; Xiaopeng Gao; Fengrui Liu
Journal:  Int J Oncol       Date:  2019-07-30       Impact factor: 5.650

6.  Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26.

Authors:  Hongwei Sun; Keqing Shi; Kai Qi; Hongru Kong; Jie Zhang; Shengjie Dai; Wen Ye; Tuo Deng; Qiye He; Mengtao Zhou
Journal:  Front Immunol       Date:  2019-12-11       Impact factor: 7.561

Review 7.  The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.

Authors:  Han Yeoung Lee; Seung Wan Son; Sokviseth Moeng; Soo Young Choi; Jong Kook Park
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

8.  Secondary loss of miR-3607 reduced cortical progenitor amplification during rodent evolution.

Authors:  Kaviya Chinnappa; Adrián Cárdenas; Anna Prieto-Colomina; Ana Villalba; Ángel Márquez-Galera; Rafael Soler; Yuki Nomura; Esther Llorens; Ugo Tomasello; José P López-Atalaya; Víctor Borrell
Journal:  Sci Adv       Date:  2022-01-12       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.